Recordati SpA (MIL:REC) Peter Lynch Fair Value: €28.82 (As of Jul. 11, 2026) — 1556% Above Median


MIL:REC Recordati SpA MIL:REC
95 GF Score
Price €51.30
GF Value €60.82
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Peter Lynch Fair Value?

Recordati SpA MIL:REC 95 Peter Lynch Fair Value is €28.82 as of Jul. 11, 2026, which is 100% below its 10-year median of 1.74. GuruFocus rates MIL:REC with a GF Score™ of 95/100 and a GF Value™ of €60.82 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 265 Drug Manufacturers companies, Recordati SpA ranks worse than 64.91% on this metric.

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Recordati SpA's PEG is 1. Recordati SpA's 5-Year TTM EBITDA Growth Rate is 11.77. Recordati SpA's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €2.45. Therefore, the Peter Lynch Fair Value for today is €28.82.

As of today (2026-07-11), Recordati SpA's share price is €51.30. Recordati SpA's Peter Lynch fair value is €28.82. Therefore, Recordati SpA's Price to Peter Lynch Fair Value Ratio for today is 1.78.


The historical rank and industry rank for Recordati SpA's Peter Lynch Fair Value or its related term are showing as below:

MIL:REC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.08   Med: 1.74   Max: 4.96
Current: 1.78


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Recordati SpA was 4.96. The lowest was 1.08. And the median was 1.74.


MIL:REC's Price-to-Peter-Lynch-Fair-Value is ranked worse than
64.91% of 265 companies
in the Drug Manufacturers industry
Industry Median: 1.29 vs MIL:REC: 1.78

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Recordati SpA  (MIL:REC) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 11.77 instead of 15 in this case.

Recordati SpA's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=51.30/28.82
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recordati SpA Peter Lynch Fair Value Related Terms


Recordati SpA Peter Lynch Fair Value Historical Data

* Premium members only.

The historical data trend for Recordati SpA's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA Peter Lynch Fair Value Chart

Recordati SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.14 0.00 9.84 15.85 25.15

Recordati SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.42 19.28 20.41 25.15 28.82

MIL:REC vs LLY, JNJ, ABBV: Peter Lynch Fair Value Comparison

For the Drug Manufacturers - General subindustry, Recordati SpA's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Price-to-Peter-Lynch-Fair-Value falls into.


MIL:REC
95GF Score
Recordati SpA MIL:REC
Peter Lynch Fair Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recordati SpA Peter Lynch Fair Value Calculation

Recordati SpA's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 11.77 *2.449
=28.82

Recordati SpA's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.45.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.

Frequently Asked Questions Learn more about Peter Lynch Fair Value →
What does a Peter Lynch Fair Value of €28.82 mean?
Recordati SpA (MIL:REC) has a Peter Lynch Fair Value of €28.82 as of Jul. 11, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Recordati SpA and its competitors. This is 1556% above median its historical median of 1.74. Over the past decade, Recordati SpA's Peter Lynch Fair Value has ranged from 1.08 to 4.96. According to the industry distribution chart, Recordati SpA ranks #172 out of 265 companies in the Drug Manufacturers industry, placing it in the top 64.9%.
Is Recordati SpA's Peter Lynch Fair Value too high?
Recordati SpA's current Peter Lynch Fair Value of €28.82 is 1556% above median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 1.08 to a high of 4.96. Based on the distribution chart, Recordati SpA ranks #172 out of 265 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Peter Lynch Fair Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #172 out of 265 companies for Peter Lynch Fair Value. This places Recordati SpA in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.29. Historically, Recordati SpA's own Peter Lynch Fair Value has ranged from 1.08 to 4.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.29, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Peter Lynch Fair Value is €28.82, which is 1556% above median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.82, compared to a current price of €51.30 — trading 15.7% below its estimated fair value. The current Peter Lynch Fair Value is €28.82, which is 1556% above median its 10-year median of 1.74. Recordati SpA's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Peter Lynch Fair Value is €28.82 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recordati SpA (MIL:REC) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of €51.30 is trading 15.7% below its estimated GF Value™ of €60.82. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for MIL:REC:

  • Peter Lynch Fair Value: €28.82 (1556% above median its 10-year median of 1.74)
  • GF Value™: €60.82 vs. price of €51.30 (15.7% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
95GF Score

Get the complete analysis for MIL:REC

Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.30
Price
€60.82
GF Value